Research at the interface of industry, academia and regulatory science

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1

    Borchers, A.T., Hagie, F., Keen, C.L. & Gershwin, M.E. Clin. Ther. 29, 1–16 (2007).

  2. 2

    Miller, S.A. J. Nutr. 123, 279–284 (1993).

  3. 3

    Collins, J.M. Chem. Biol. Interact. 134, 237–242 (2001).

  4. 4

    Peters, T.S. Toxicol. Pathol. 33, 146–154 (2005).

  5. 5

    Voisin, E.M., Ruthsatz, M., Collins, J.M. & Hoyle, P.C. Regul. Toxicol. Pharmacol. 12, 107–116 (1990).

  6. 6

    Jacobs, A. & Jacobson-Kram, D. Toxicol. Sci. 81, 260–262 (2004).

  7. 7

    Jacobson-Kram, D. & Contrera, J.F. Toxicol. Sci. 96, 16–20 (2007).

  8. 8

    Miller, M.A. Int. J. Toxicol. 20, 149–152 (2001).

  9. 9

    MacGregor, J.T. Toxicol. Sci. 75, 236–248 (2003).

  10. 10

    Tong, W. et al. Environ. Health Perspect. 111, 1819–1826 (2003).

  11. 11

    Gutman, S. & Kessler, L.G. Nat. Rev. Cancer 6, 565–571 (2006).

  12. 12

    Lesko, L.J. Clin. Pharmacol. Ther. 81, 807–816 (2007).

  13. 13

    Anonymous. Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products (FDA, Washington, DC, 2004; accessed 23 April 2010). http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm

  14. 14

    Woosley, R.L. & Cossman, J. Clin. Pharmacol. Ther. 81, 129–133 (2007).

  15. 15

    Anonymous. US Food and Drug Administration. Critical Path Opportunities List - March 2006 (FDA, Washington, DC, 2006; accessed 23 April 2010). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf

  16. 16

    Irwin, D.A. & Klenow, P.J. Proc. Natl. Acad. Sci. USA 93, 12739–12742 (1996).

  17. 17

    The Food and Drug Adminstration. Fed. Regist. 70, 74823–74826 (2005).

  18. 18

    Marrer, E. & Dieterle, F. Chem. Biol. Drug Des. 69, 381–394 (2007).

  19. 19

    Mattes, W.B. Methods Mol. Biol. 460, 221–238 (2008).

  20. 20

    Kim, W.R., Flamm, S.L., Di Bisceglie, A.M. & Bodenheimer, H.C. Hepatology 47, 1363–1370 (2008).

  21. 21

    Zweig, M.H. & Campbell, G. Clin. Chem. 39, 561–577 (1993).

  22. 22

    Senior, J.R. Clin. Liver Dis. 11, 507–524 (2007).

  23. 23

    The Food and Drug Adminstration. Fed. Regist. 72, 60681–60682 (2007).

  24. 24

    Wagner, J.A., Williams, S.A. & Webster, C.J. Clin. Pharmacol. Ther. 81, 104–107 (2007).

  25. 25

    Lee, J.W. et al. Pharm. Res. 23, 312–328 (2006).

  26. 26

    Wagner, J.A. Annu. Rev. Pharmacol. Toxicol. 48, 631–651 (2008).

  27. 27

    Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology 245, 219–223 (2008).

  28. 28

    Schetz, M., Dasta, J., Goldstein, S. & Golper, T. Curr. Opin. Crit. Care 11, 555–565 (2005).

Download references

Author information

Correspondence to William B Mattes.

Ethics declarations

Competing interests

F.D.S. is an employee of Merck and J.V. is an employee of Novartis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Mattes, W., Walker, E., Abadie, E. et al. Research at the interface of industry, academia and regulatory science. Nat Biotechnol 28, 432–433 (2010) doi:10.1038/nbt0510-432

Download citation

Further reading